Aytu Total Current Liabilities vs Common Stock Analysis

AYTU Stock

USD 1.62 0.02 1.25%

Aytu BioScience financial indicator trend analysis is way more than just evaluating Aytu BioScience prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aytu BioScience is a good investment. Please check the relationship between Aytu BioScience Total Current Liabilities and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.

Total Current Liabilities vs Common Stock

Total Current Liabilities vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aytu BioScience Total Current Liabilities account and Common Stock. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Aytu BioScience's Total Current Liabilities and Common Stock is -0.39. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock in the same time period over historical financial statements of Aytu BioScience, assuming nothing else is changed. The correlation between historical values of Aytu BioScience's Total Current Liabilities and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Aytu BioScience are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Current Liabilities i.e., Aytu BioScience's Total Current Liabilities and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Aytu BioScience balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aytu BioScience are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock

Most indicators from Aytu BioScience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aytu BioScience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.At this time, Aytu BioScience's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 39.82 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (377.02) in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	52.3M	66.6M	54.6M	57.3M
Total Revenue	96.7M	107.4M	81.0M	85.1M

Gross Profit Total Revenue

Aytu BioScience fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock Total Equity	Other Current Assets	Common Stock	Net Tangible Assets	Current Deferred Revenue	Non Currrent Assets Other	Retained Earnings Total Equity
Total Assets		0.79	0.57	0.94	0.92	0.86	-0.56	-0.72	0.97	0.91	0.97	0.91	0.47	0.76	0.86	0.95	0.91	0.98	0.67	-0.43	0.61	-0.43	-0.26	0.83	0.52	-0.8
Short Long Term Debt Total	0.79		0.36	0.74	0.75	0.78	-0.42	-0.58	0.83	0.74	0.83	0.74	0.22	0.57	0.68	0.73	0.76	0.74	0.69	-0.7	0.39	-0.7	-0.35	0.69	0.43	-0.79
Other Current Liab	0.57	0.36		0.7	0.23	0.45	0.0	-0.95	0.58	0.33	0.4	0.33	0.86	0.81	0.88	0.77	0.61	0.67	-0.04	-0.35	0.94	-0.35	-0.57	0.76	0.79	-0.66
Total Current Liabilities	0.94	0.74	0.7		0.76	0.88	-0.27	-0.83	0.91	0.73	0.89	0.73	0.64	0.74	0.91	0.98	0.97	0.94	0.65	-0.39	0.65	-0.39	-0.53	0.94	0.65	-0.74
Total Stockholder Equity	0.92	0.75	0.23	0.76		0.78	-0.74	-0.41	0.89	0.96	0.95	0.96	0.13	0.54	0.61	0.74	0.76	0.87	0.74	-0.35	0.36	-0.35	0.06	0.6	0.22	-0.64
Property Plant And Equipment Net	0.86	0.78	0.45	0.88	0.78		-0.21	-0.59	0.86	0.68	0.9	0.68	0.24	0.51	0.7	0.82	0.96	0.79	0.73	-0.3	0.45	-0.3	-0.5	0.9	0.3	-0.61
Net Debt	-0.56	-0.42	0.0	-0.27	-0.74	-0.21		0.13	-0.55	-0.83	-0.56	-0.83	0.07	-0.47	-0.3	-0.34	-0.19	-0.56	-0.27	0.3	-0.24	0.3	-0.56	-0.04	-0.01	0.51
Retained Earnings	-0.72	-0.58	-0.95	-0.83	-0.41	-0.59	0.13		-0.72	-0.5	-0.59	-0.5	-0.86	-0.9	-0.97	-0.89	-0.75	-0.8	-0.17	0.49	-0.88	0.49	0.61	-0.84	-0.83	0.83
Accounts Payable	0.97	0.83	0.58	0.91	0.89	0.86	-0.55	-0.72		0.91	0.96	0.91	0.42	0.75	0.84	0.92	0.88	0.96	0.61	-0.44	0.65	-0.44	-0.27	0.84	0.46	-0.8
Cash	0.91	0.74	0.33	0.73	0.96	0.68	-0.83	-0.5	0.91		0.92	1.0	0.21	0.68	0.67	0.76	0.69	0.9	0.6	-0.41	0.49	-0.41	0.11	0.57	0.3	-0.74
Non Current Assets Total	0.97	0.83	0.4	0.89	0.95	0.9	-0.56	-0.59	0.96	0.92		0.92	0.27	0.64	0.74	0.87	0.9	0.92	0.76	-0.39	0.47	-0.39	-0.22	0.79	0.35	-0.73
Cash And Short Term Investments	0.91	0.74	0.33	0.73	0.96	0.68	-0.83	-0.5	0.91	1.0	0.92		0.21	0.68	0.67	0.76	0.68	0.89	0.6	-0.42	0.49	-0.42	0.11	0.57	0.3	-0.74
Common Stock Shares Outstanding	0.47	0.22	0.86	0.64	0.13	0.24	0.07	-0.86	0.42	0.21	0.27	0.21		0.69	0.79	0.69	0.5	0.58	0.03	-0.28	0.7	-0.28	-0.54	0.6	0.9	-0.51
Non Current Liabilities Total	0.76	0.57	0.81	0.74	0.54	0.51	-0.47	-0.9	0.75	0.68	0.64	0.68	0.69		0.92	0.85	0.64	0.84	0.13	-0.5	0.87	-0.5	-0.33	0.67	0.69	-0.91
Other Stockholder Equity	0.86	0.68	0.88	0.91	0.61	0.7	-0.3	-0.97	0.84	0.67	0.74	0.67	0.79	0.92		0.96	0.84	0.91	0.34	-0.52	0.85	-0.52	-0.51	0.87	0.8	-0.88
Total Liab	0.95	0.73	0.77	0.98	0.74	0.82	-0.34	-0.89	0.92	0.76	0.87	0.76	0.69	0.85	0.96		0.93	0.96	0.54	-0.44	0.75	-0.45	-0.5	0.92	0.7	-0.83
Property Plant And Equipment Gross	0.91	0.76	0.61	0.97	0.76	0.96	-0.19	-0.75	0.88	0.69	0.9	0.68	0.5	0.64	0.84	0.93		0.87	0.7	-0.34	0.56	-0.34	-0.57	0.95	0.53	-0.69
Total Current Assets	0.98	0.74	0.67	0.94	0.87	0.79	-0.56	-0.8	0.96	0.9	0.92	0.89	0.58	0.84	0.91	0.96	0.87		0.56	-0.44	0.72	-0.44	-0.26	0.82	0.59	-0.82
Short Term Debt	0.67	0.69	-0.04	0.65	0.74	0.73	-0.27	-0.17	0.61	0.6	0.76	0.6	0.03	0.13	0.34	0.54	0.7	0.56		-0.3	-0.1	-0.3	-0.2	0.52	0.21	-0.3
Common Stock Total Equity	-0.43	-0.7	-0.35	-0.39	-0.35	-0.3	0.3	0.49	-0.44	-0.41	-0.39	-0.42	-0.28	-0.5	-0.52	-0.44	-0.34	-0.44	-0.3		-0.39	1.0	0.16	-0.32	-0.59	0.67
Other Current Assets	0.61	0.39	0.94	0.65	0.36	0.45	-0.24	-0.88	0.65	0.49	0.47	0.49	0.7	0.87	0.85	0.75	0.56	0.72	-0.1	-0.39		-0.39	-0.34	0.69	0.64	-0.72
Common Stock	-0.43	-0.7	-0.35	-0.39	-0.35	-0.3	0.3	0.49	-0.44	-0.41	-0.39	-0.42	-0.28	-0.5	-0.52	-0.45	-0.34	-0.44	-0.3	1.0	-0.39		0.16	-0.32	-0.6	0.67
Net Tangible Assets	-0.26	-0.35	-0.57	-0.53	0.06	-0.5	-0.56	0.61	-0.27	0.11	-0.22	0.11	-0.54	-0.33	-0.51	-0.5	-0.57	-0.26	-0.2	0.16	-0.34	0.16		-0.68	-0.48	0.34
Current Deferred Revenue	0.83	0.69	0.76	0.94	0.6	0.9	-0.04	-0.84	0.84	0.57	0.79	0.57	0.6	0.67	0.87	0.92	0.95	0.82	0.52	-0.32	0.69	-0.32	-0.68		0.59	-0.67
Non Currrent Assets Other	0.52	0.43	0.79	0.65	0.22	0.3	-0.01	-0.83	0.46	0.3	0.35	0.3	0.9	0.69	0.8	0.7	0.53	0.59	0.21	-0.59	0.64	-0.6	-0.48	0.59		-0.6
Retained Earnings Total Equity	-0.8	-0.79	-0.66	-0.74	-0.64	-0.61	0.51	0.83	-0.8	-0.74	-0.73	-0.74	-0.51	-0.91	-0.88	-0.83	-0.69	-0.82	-0.3	0.67	-0.72	0.67	0.34	-0.67	-0.6

Click cells to compare fundamentals

Aytu BioScience Account Relationship Matchups

Aytu BioScience fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	152.8M	265.7M	137.6M	136.5M	118.1M	124.0M
Other Current Liab	14.9M	7.4M	49.5M	55.5M	47.5M	49.9M
Total Current Liabilities	28.3M	109.4M	64.4M	69.0M	62.2M	65.3M
Total Stockholder Equity	95.0M	137.6M	46.1M	39.4M	27.7M	24.5M
Property Plant And Equipment Net	892.6K	8.7M	6.3M	3.9M	1.5M	1.4M
Net Debt	(46.1M)	(21.3M)	(1.2M)	(6.6M)	(4.9M)	(5.1M)
Retained Earnings	(120.0M)	(178.3M)	(288.5M)	(304.1M)	(320.0M)	(304.0M)
Accounts Payable	11.8M	19.3M	11.0M	13.5M	10.4M	5.4M
Cash	48.1M	49.6M	19.4M	23.0M	20.0M	12.0M
Non Current Assets Total	77.9M	160.4M	77.7M	63.6M	56.2M	31.3M
Cash And Short Term Investments	48.1M	49.6M	19.4M	23.0M	20.0M	12.1M
Common Stock Shares Outstanding	226.0K	837.3K	1.5M	3.3M	5.5M	5.8M
Liabilities And Stockholders Equity	152.8M	265.7M	137.6M	136.5M	118.1M	124.0M
Non Current Liabilities Total	29.5M	18.7M	27.1M	28.1M	28.2M	29.6M
Other Stockholder Equity	215.0M	315.9M	331.4M	343.5M	347.7M	365.1M
Total Liab	57.8M	128.1M	91.5M	97.1M	90.4M	94.9M
Property Plant And Equipment Gross	1.2M	8.7M	6.3M	3.9M	3.6M	3.8M
Total Current Assets	75.0M	105.2M	59.9M	72.8M	61.9M	65.0M
Common Stock Total Equity	179.0	1.8K	12.6K	3K	2.7K	2.6K
Other Current Assets	5.7M	1.0M	8.0M	8.9M	5.6M	5.9M
Common Stock	12.6K	3K	4K	1K	900.0	855.0
Net Tangible Assets	34.7M	(13.7M)	(24.5M)	(19.6M)	(17.7M)	(16.8M)
Non Currrent Assets Other	33.0K	465K	766K	792K	2.2M	2.3M
Intangible Assets	48.9M	85.5M	70.6M	59.0M	52.5M	35.8M
Property Plant Equipment	258.5K	8.7M	6.3M	3.9M	4.4M	4.7M
Other Liab	28.8M	15.9M	12.8M	13.4M	15.4M	12.2M
Other Assets	33.0K	465K	766K	792K	910.8K	956.3K
Net Receivables	5.2M	28.2M	21.7M	28.9M	23.6M	24.8M
Inventory	10.0M	16.3M	10.8M	12.0M	12.6M	6.6M
Non Current Liabilities Other	18.3M	15.9M	12.8M	7.0M	4.5M	4.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC